-
Results for the First Quarter 2019
Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…
Read more -
Annual Report 2018
During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…
Read more -
Results for Fourth Quarter and Preliminary Results for Medistim for 2018
Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…
Read more -
Results for the Third Quarter 2018
Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…
Read more -
REQUEST Final Results: Strengthening the Recommendation for Medistim’s Dual Technology
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and Transit Time Flow Measurement (TTFM) performed with Medistim's VeriQ C or MiraQ devices will change the…
Read more -
Results for the Second Quarter 2018
Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…
Read more -
REQUEST Interim Results: Significant Impact on Surgical Strategy with Medistim’s Devices
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim’s VeriQ C or MiraQ devices will change the…
Read more -
Results for the First Quarter 2018
Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…
Read more -
Annual Report 2017
We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures…
Read more -
Renewed NICE recommendation for adopting Medistim technology in the NHS
Approximately 17,000 isolated coronary artery bypass graft (CABG) operations are performed in the UK each year. In addition, a substantial proportion of patients having other cardiac surgery have concomitant CABG. The National Institute for Health…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.